OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC filed a Schedule 13D with the SEC on November 6, 2026, disclosing beneficial ownership of 3,589,132 shares of Aspen Neuroscience, Inc. common stock following the company's initial public offering, with the triggering event dated November …
Executive Chairman Richard D. Kinder filed a Form 4 with the SEC on November 6, 2026, disclosing a purchase of 500,000 shares of Kinder Morgan, Inc. Class P Common Stock at a weighted average price of $29.9884 per share.
Harraden Circle Investments, LLC and Frederick V. Fortmiller, Jr. filed an amended beneficial ownership statement with the SEC on November 6, 2026, disclosing a combined 13.89% stake in Calisa Acquisition Corp's Ordinary Shares as of October 31, 2026.
Harraden Circle Investments, LLC and Frederick V. Fortmiller, Jr. filed a Schedule 13G with the SEC on November 6, 2026, disclosing a beneficial ownership position in the Ordinary Shares of Calisa Acquisition Corp as of September 30, 2026.
Harraden Circle Investments, LLC and Frederick V. Fortmiller, Jr. filed a Schedule 13G with the SEC on November 6, 2026, disclosing beneficial ownership of Class A shares of Texas Ventures Acquisition III Corp as of October 31, 2026.
Qualys, Inc. Chief Financial Officer Joo Mi Kim reported the acquisition of 26,179 restricted stock units on November 5, 2026, in a statement of changes in beneficial ownership filed with the SEC on November 6, 2026.
Qualys, Inc. Chief Legal Officer Bruce K. Posey reported the acquisition of 15,241 restricted stock units on November 5, 2026, in a statement of changes in beneficial ownership filed with the SEC on November 6, 2026.
Mondelez International, Inc. Chief Executive Officer and Director Dirk Van de Put filed a Form 4 on November 6, 2026, disclosing the exercise of stock options and same-day sales of Class A Common Stock on November 4 and 5, 2026, pursuant to a Rule …
Jack Sinclair, Chief Executive Officer and Director of Sprouts Farmers Market, Inc., filed a Form 4 on November 6, 2026, disclosing the exercise of stock options and sale of common stock on November 4 and November 5, 2026, pursuant to a Rule 10b5-1 trading …
Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, Inc., filed a Form 4 on November 6, 2026, disclosing a sale of common stock on November 5, 2026, to cover tax withholding obligations from vesting RSUs.